CHK1/2 inhibition has recently been reported to potentiate the antitumor immune response and sensitize cells to ICBs, such as glioblastoma multiforme, head and neck squamous cell carcinoma, and small cell lung cancers [18, 19, 57–59]. Here, CHEK1 is linked to head and neck squamous cell carcinoma.